1. Executive Summary |
2. Global Orphan Drugs Market Introduction |
2.1. Global Orphan Drugs Market – Taxonomy |
2.2. Global Orphan Drugs Market –Definitions |
2.2.1. Disease Type |
2.2.2. Indication |
2.2.3. Distribution Channel |
2.2.4. End User |
3. Global Orphan Drugs Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Orphan Drugs Market Dynamic |
3.6. Global Orphan Drugs Market – Competition Landscape |
3.7. Epidemiology |
4. Global Orphan Drugs Market Analysis,2017 – 2021 and Forecast, 2022 – 2028 |
4.1. Market Analysis,2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Orphan Drugs Market, By Disease Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.1. Oncologic Diseases |
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Metabolic Diseases |
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Hematologic and Immunologic Diseases |
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Infectious Diseases |
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Neurologic Diseases |
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Other Rare Diseases |
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6. Global Orphan Drugs Market Forecast, By Indication, 2017 – 2021 and Forecast, 2022 – 2028(Revenue, USD Mn) |
6.1. Non-Hodgkin Lymphoma |
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Acute Myeloid Leukemia |
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Cystic Fibrosis |
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Glioma |
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Pancreatic Cancer |
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Ovarian Cancer |
6.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. Multiple Myeloma |
6.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
6.8. Duchenne Muscular Dystrophy |
6.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.8.3. Market Opportunity Analysis |
6.9. Graft vs Host Disease |
6.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.9.3. Market Opportunity Analysis |
6.10. Renal Cell Carcinoma |
6.10.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.10.3. Market Opportunity Analysis |
6.11. Others |
6.11.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.11.3. Market Opportunity Analysis |
7. Global Orphan Drugs Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028(Revenue, USD Mn) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Stores |
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Others |
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8. Global Orphan Drugs Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.1. North America |
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Orphan Drugs Market – Opportunity Analysis Index, By Disease Type, Indication, Distribution Channel and Region, 2022 – 2028 |
9. North America Orphan Drugs MarketAnalysis,2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
9.1. By Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Oncologic Diseases |
9.1.2. Metabolic Diseases |
9.1.3. Hematologic and Immunologic Diseases |
9.1.4. Infectious Diseases |
9.1.5. Neurologic Diseases |
9.1.6. Other Rare Diseases |
9.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.2.1. Non-Hodgkin Lymphoma |
9.2.2. Acute Myeloid Leukemia |
9.2.3. Cystic Fibrosis |
9.2.4. Glioma |
9.2.5. Pancreatic Cancer |
9.2.6. Ovarian Cancer |
9.2.7. Multiple Myeloma |
9.2.8. Duchenne Muscular Dystrophy |
9.2.9. Graft vs Host Disease |
9.2.10. Renal Cell Carcinoma |
9.2.11. Others |
9.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Hospital Pharmacies |
9.3.2. Retail Pharmacies |
9.3.3. Online Stores |
9.3.4. Others |
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. USA |
9.4.2. Canada |
9.5. North America Orphan Drugs Market – Opportunity Analysis Index, By Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028 |
9.6. North America Orphan Drugs Market Dynamics – Trends |
10. Europe Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
10.1. By Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Oncologic Diseases |
10.1.2. Metabolic Diseases |
10.1.3. Hematologic and Immunologic Diseases |
10.1.4. Infectious Diseases |
10.1.5. Neurologic Diseases |
10.1.6. Other Rare Diseases |
10.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Non-Hodgkin Lymphoma |
10.2.2. Acute Myeloid Leukemia |
10.2.3. Cystic Fibrosis |
10.2.4. Glioma |
10.2.5. Pancreatic Cancer |
10.2.6. Ovarian Cancer |
10.2.7. Multiple Myeloma |
10.2.8. Duchenne Muscular Dystrophy |
10.2.9. Graft vs Host Disease |
10.2.10. Renal Cell Carcinoma |
10.2.11. Others |
10.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Hospital Pharmacies |
10.3.2. Retail Pharmacies |
10.3.3. Online Stores |
10.3.4. Others |
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Spain |
10.4.5. Italy |
10.4.6. Russia |
10.4.7. Poland |
10.4.8. Rest of Europe |
10.5. Europe Orphan Drugs Market – Opportunity Analysis Index, By Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028 |
10.6. Europe Orphan Drugs Market Dynamics – Trends |
11. Asia-Pacific Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
11.1. By Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Oncologic Diseases |
11.1.2. Metabolic Diseases |
11.1.3. Hematologic and Immunologic Diseases |
11.1.4. Infectious Diseases |
11.1.5. Neurologic Diseases |
11.1.6. Other Rare Diseases |
11.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Non-Hodgkin Lymphoma |
11.2.2. Acute Myeloid Leukemia |
11.2.3. Cystic Fibrosis |
11.2.4. Glioma |
11.2.5. Pancreatic Cancer |
11.2.6. Ovarian Cancer |
11.2.7. Multiple Myeloma |
11.2.8. Duchenne Muscular Dystrophy |
11.2.9. Graft vs Host Disease |
11.2.10. Renal Cell Carcinoma |
11.2.11. Others |
11.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Hospital Pharmacies |
11.3.2. Retail Pharmacies |
11.3.3. Online Stores |
11.3.4. Others |
11.4. Country Analysis2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Japan |
11.4.2. China |
11.4.3. India |
11.4.4. ASEAN |
11.4.5. Australia & New Zealand |
11.4.6. Rest of Asia-Pacific |
11.5. Asia-Pacific Orphan Drugs Market – Opportunity Analysis Index, By Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028 |
11.6. Asia-Pacific Orphan Drugs Market Dynamics – Trends |
12. Latin America Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
12.1. By Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Oncologic Diseases |
12.1.2. Metabolic Diseases |
12.1.3. Hematologic and Immunologic Diseases |
12.1.4. Infectious Diseases |
12.1.5. Neurologic Diseases |
12.1.6. Other Rare Diseases |
12.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Non-Hodgkin Lymphoma |
12.2.2. Acute Myeloid Leukemia |
12.2.3. Cystic Fibrosis |
12.2.4. Glioma |
12.2.5. Pancreatic Cancer |
12.2.6. Ovarian Cancer |
12.2.7. Multiple Myeloma |
12.2.8. Duchenne Muscular Dystrophy |
12.2.9. Graft vs Host Disease |
12.2.10. Renal Cell Carcinoma |
12.2.11. Others |
12.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Hospital Pharmacies |
12.3.2. Retail Pharmacies |
12.3.3. Online Stores |
12.3.4. Others |
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Mexico |
12.4.3. Argentina |
12.4.4. Rest of Latin America |
12.5. Latin America Orphan Drugs Market – Opportunity Analysis Index, By Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028 |
12.6. Latin America Orphan Drugs Market Dynamics – Trends |
13. Middle East and Africa Orphan Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
13.1. By Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Oncologic Diseases |
13.1.2. Metabolic Diseases |
13.1.3. Hematologic and Immunologic Diseases |
13.1.4. Infectious Diseases |
13.1.5. Neurologic Diseases |
13.1.6. Other Rare Diseases |
13.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.2.1. Non-Hodgkin Lymphoma |
13.2.2. Acute Myeloid Leukemia |
13.2.3. Cystic Fibrosis |
13.2.4. Glioma |
13.2.5. Pancreatic Cancer |
13.2.6. Ovarian Cancer |
13.2.7. Multiple Myeloma |
13.2.8. Duchenne Muscular Dystrophy |
13.2.9. Graft vs Host Disease |
13.2.10. Renal Cell Carcinoma |
13.2.11. Others |
13.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Hospital Pharmacies |
13.3.2. Retail Pharmacies |
13.3.3. Online Stores |
13.3.4. Others |
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Gulf Cooperation Council (GCC) Countries |
13.4.2. Israel |
13.4.3. South Africa |
13.4.4. Rest of MEA |
13.5. MEA Orphan Drugs Market – Opportunity Analysis Index, By Disease Type, Indication, Distribution Channel, and Country, 2022 – 2028 |
13.6. MEA Orphan Drugs Market Dynamics – Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Indication& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. Astrazeneca Plc |
14.2.2. AOP Orphan Pharmaceuticals GmbH |
14.2.3. Eli Lilly And Co. |
14.2.4. F. Hoffmann-La Roche Ltd. |
14.2.5. Gilead Sciences Inc. |
14.2.6. Johnson & Johnson |
14.2.7. Merck & Co. |
14.2.8. Novartis Ag |
14.2.9. Pfizer Inc. |
14.2.10. Sanofi-Aventis |
14.2.11. Takeda Pharmaceutical Co., Ltd. |
14.2.12. Teva Pharmaceutical Industries Ltd. |
15. Research Methodology |
16. Key Assumptions and Acronyms |
Reviews
There are no reviews yet.